x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001097
| Product Information | |
|---|---|
| Product Name | Irisin ELISA Kit |
| Species | Human |
| Description | The Irisin ELISA kit is to be used for the in vitro quantitative determination of human irisin in cell culture supernatants, serum and plasma. It should also work for the in vitro quantitative determination of irisin in mouse, rat and monkey biological samples. A polyclonal antibody recognizing native irisin reacts with a series of predetermined recombinant irisin standard proteins or samples under competition in the irisin-coated plate. Their relative reactivity is plotted with that of the standard proteins. Detection limit: 1 ng/ml. Note: The Limit of detection was measured by adding two standard deviations to the mean value of 50 zero standard. Assay Range: 0.001 ug/ml - 5 ug/ml. Irisin levels range in human plasma and serum from 0.2 to > 2 ug /ml. |
| Sample Types | Cell Culture Supernatant, Serum, Plasma |
| Detection Range | 0.001 µg/mL - 5 µg/mL |
| Sensitivity | 1 ng/mL |
| Target Information | |
|---|---|
| Target Name | FNDC5 |
| UniProt No. | Q8NAU1 |
| Gene ID | 252995 |
| Alternative Names | Fibronectin type III domain containing 5; Fibronectin type III domain-containing protein 5; Fibronectin type III repeat containing protein 2; Fibronectin type III repeat-containing protein 2; FNDC 5; Fndc5; FNDC5_HUMAN; FRCP2; irisin |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
